Tonight's digest has 19 items across medchem, pharmacology and industry; computational had no entries. Chemistry runs from FGFR2/4 PROTACs to MCT1 and ALDH1B1 inhibitors, pharmacology from M4 PAM mechanism to CYP metabolism, and the news is led by Lilly's retatrutide head-to-head win and the Takeda/Innovent Claudin 18.2 ADC.
2026-10-28 · ⚗️SULT2B1b (cholesterol sulfotransferase) / azasteroid small molecules · ACS Chemical Biology (ACS)
- Reports a new azasteroid class of inhibitors against SULT2B1b, the enzyme producing the immunosuppressive metabolite cholesterol sulfate.
- Compounds are described as more potent and more selective than earlier inhibitors, and engage the enzyme in a pose distinct from its natural substrates.
- In mouse tumors they lower cholesterol sulfate, and the authors propose pairing them with immune checkpoint blockade.
💡 PointsBased on the abstractA distinct binding pose versus the natural substrate is the interesting part: it suggests a route to selectivity over other SULTs, which steroid-like scaffolds usually struggle with. I'd want the SULT2A1/other-isoform panel and in vivo exposure before believing the immuno-oncology story. Does the checkpoint combination hold up beyond mouse models?
Small-Molecule Inhibitors of Cholesterol Sulfotransferase as Immunomodulatory Agents ↗
2026-10-27 · ⚗️MCT1 (monocarboxylate transporter 1) / small molecule · ChemMedChem (Wiley)
- A small set of new 5-arylpyrazoles was made via a multistep route, offering a fresh scaffold against MCT1, a lactate transporter tied to tumor metabolism.
- In a 3-bromopyruvate-based transport screen, the 3-fluorophenyl analogue 17c curbed MCT1 activity at concentrations below those that harmed cells.
- 17c also caused intracellular lactate to build up across several cell lines, consistent with transporter blockade, and is proposed as a lead for further optimization.
💡 PointsBased on the abstractEleven compounds and one hit with lactate accumulation below cytotoxic doses is a reasonable start, but no binding data means I can't say it's on-target MCT1 rather than a general transport or metabolic effect. Low-yield multistep chemistry would also slow SAR. I'd first test MCT4 selectivity and compare against AZD3965-type chemotypes.
Synthesis and Biological Evaluation of 5‐Arylpyrazoles as Potential MCT 1 Inhibitors Targeting Lactate Transport ↗
2026-10-26 · ⚗️Butyrophilin 3A3 (BTN3A3) / phosphonate analogs of mevalonate diphosphate · ACS Medicinal Chemistry Letters (ACS)
- Phosphonate versions of mevalonate diphosphate were made and tested for their ability to activate Vγ9Vδ2 T cells.
- Several analogs prompted interferon-γ release from effector cells, though none strongly expanded naive cells.
- The lead analog beat the natural metabolite, worked preferentially via BTN3A3-expressing cells, withstood statin treatment, and acted synergistically with a BTN3A1 agonist.
💡 PointsBased on the abstractBeating the natural metabolite while surviving statin treatment hints these phosphonates are not simply riding the mevalonate pathway, and the BTN3A3 bias is a new angle versus BTN3A1-centred phosphoantigen work. But charged diphosphate mimics have a classic permeability and stability problem. I'd ask how the lead behaves in cells without prodrugging.
Synthesis and Evaluation of Mevalonate Diphosphate Analogs as Butyrophilin 3A3 Ligands ↗
2026-10-16 · ⚗️FGFR2/FGFR4 / VHL-recruiting PROTAC degraders · European Journal of Medicinal Chemistry (Elsevier)
- The team linked an in-house pan-FGFR inhibitor to a VHL ligand, building a PROTAC series.
- Two lead compounds degraded FGFR2 and FGFR4 selectively through the ubiquitin-proteasome system and showed potent antiproliferative effects in cells.
- In a gastric cancer xenograft model they shrank tumors with target degradation, and ternary complex modeling rationalized the isoform selectivity. The authors describe these as the first FGFR4-directed PROTACs.
💡 PointsBased on the abstractA pan-FGFR warhead yielding FGFR2/4-selective degraders is the real story: degradation selectivity comes from ternary-complex geometry, not binding affinity, so the SAR lives in the linker and VHL exit vector. FGFR4 has been mostly covalent-inhibitor territory, so this is a genuinely different handle. I'd check FGFR1/3 sparing and hook effect.
Identification of selective FGFR2/4 degraders with potent antiproliferative activity ↗
2026-10-10 · ⚗️PAR4 (protease-activated receptor 4) small-molecule antagonists · Bioorganic & Medicinal Chemistry Letters (Elsevier)
- A Bristol-Myers Squibb team reports a quinoline-based series of PAR4 antagonists, found through iterative structure-activity optimization, that reaches very high potency against the target.
- The compounds also show favorable oral exposure and peak plasma levels in rats, which supports further development as antithrombotic agents.
💡 PointsBased on the abstractPotency plus rat oral exposure is a decent start, but that's all this tells me. For an antithrombotic target the whole game is the window between antiplatelet effect and bleeding, and nothing here speaks to it. I'd want PAR1 selectivity, human versus rodent activity, and any efficacy data before getting excited about the quinoline.
Benzothiazoloquinolines as protease-activated receptor 4 (PAR4) antagonists with excellent rat pharmacokinetic properties ↗
2026-10-09 · ⚗️ALDH1B1 / guanidinyl small-molecule inhibitors (IGUANA series) · Journal of Medicinal Chemistry (ACS)2026, 69 (20), 23428–23448
- SAR work on a guanidine-based ALDH1B1 inhibitor series explored the core, the catalytic-site aryl ring and the biaryl group.
- Earlier compounds proved metabolically unstable and were pumped out of intestinal epithelial cells.
- Replacing the biaryl and altering the core gave an aryl-alkyl ether, IGUANA-5, which inhibits colon and pancreatic cancer spheroid growth and shows improved in vitro and in vivo pharmacology.
💡 PointsBased on the abstractIs the ADME fix real or just cosmetic? Swapping the biaryl for an aryl-alkyl ether is a cheap, tractable change that tackles both metabolic lability and efflux, which is the right diagnosis for a guanidine series. I'd want isoform selectivity against ALDH1A1/ALDH2 and permeability data before trusting the spheroid readout.
Development of Next-Generation ALDH1B1 Inhibitors with Enhanced Pharmacological and Functional Properties ↗
2026-10-09 · ⚗️EGFR kinase domain / ATP-allosteric bivalent inhibitors · Journal of Medicinal Chemistry (ACS)2026, 69 (20), 24838–24861
- Studies ATP-site/allosteric bivalent EGFR inhibitors, where two ligands bound in neighbouring pockets are joined by a linker.
- A systematic SAR series shows that both linker length and attachment points can drive large potency improvements.
- Structural data and simulations point to maximal linker flexibility as the key design criterion, offering a framework that extends to fragment-based drug discovery.
💡 PointsBased on the abstractLinker flexibility winning out is the interesting part: for a bivalent ATP-site/allosteric binder, I'd expect a rigid, pre-organized linker to pay off, so this suggests the two pockets are only loosely coupled. Attachment-point sensitivity is what I'd mine first. I'd want selectivity over WT EGFR and the molecular weight/permeability cost before calling it tractable.
Deciphering the Structure−Activity Relationships Underpinning the Linkerology of Bivalent EGFR Inhibitors ↗
2026-10-09 · ⚗️NLRP3 / autophagy-targeting (LC3-recruiting) bifunctional degraders · Journal of Medicinal Chemistry (ACS)2026, 69 (20), 24400–24419
- Starting from an NLRP3 inhibitor known to engage both LC3 and NLRP3, the authors mapped the groups needed for NLRP3 binding and built bivalent autophagy-targeting degraders from it.
- One lead degrader, M3, emerged as the strongest NLRP3 degrader in the series.
- In a colitis model, M3 gave more lasting anti-inflammatory benefit than its inhibitor precursor, supporting degradation over inhibition for this disease.
💡 PointsBased on the abstractDegradation beating inhibition on durability is the expected payoff of removing the protein rather than occupying it. Starting from a dual LC3/NLRP3 binder is a smart shortcut, but I'd worry the LC3 handle is carried by the same pharmacophore. I'd want a clean separation of NLRP3 binding from LC3 binding and the exposure data.
Beyond Inhibition: Targeted Degradation of NLRP3 by Autophagy-Tethering Bifunctional Compounds as a Therapy for Inflammatory Bowel Disease ↗
2026-10-27 · 🧬CHI3L1–Gal3BP complex stabilizer (LZ6) · bioRxiv
- A screen found LZ6, which strengthens CHI3L1 binding to Gal3BP and reduces galectin-3 engagement in vitro.
- It pushed macrophages toward an anti-tumor state in patient-derived glioblastoma cultures and orthotopic GL261 tumors.
- Oral dosing extended survival in mice, and more so alongside anti-PD-1.
💡 PointsBased on the abstractStabilizing a protein complex rather than blocking it is an unusual pharmacological idea, and the oral survival benefit in an orthotopic model is the interesting part. But GL261 is a notoriously immunogenic mouse line that flatters checkpoint combinations, and glioblastoma has repeatedly failed to follow it. I'd need brain exposure and target engagement data before taking the mechanism seriously.
Stabilizing the CHI3L1-Gal3BP complex remodels the glioblastoma immune microenvironment and synergizes with PD-1 blockade ↗
2026-10-27 · 🧬RyR2 inhibitor / cyclic oligomeric depsipeptide (ent-verticilide) · bioRxiv
- The ADME profile of the RyR2-selective depsipeptide was worked up in rats and human liver microsomes: highly plasma-protein bound, rapidly metabolized, with oral bioavailability in the low range.
- Limited intestinal availability and CYP-mediated first-pass metabolism were identified as the main barriers to oral exposure.
💡 PointsBased on the abstractA cyclic depsipeptide that is both permeability-limited and CYP-cleared is a hard combination to fix, and this is the data that tells the team where to push. With high protein binding, the unbound exposure at an efficacious dose is the number I'd want next, along with which CYPs are involved, since that decides the interaction risk in arrhythmia patients who are often on several drugs.
Characterization of the Preclinical in Vitro and in Vivo Pharmacokinetic Properties of the Cyclic Oligomeric Depsipeptide Ryanodine Receptor 2 Inhibitor ent-Verticilide ↗
2026-10-27 · 🧬M4 muscarinic receptor positive allosteric modulator (VU0467154) · bioRxiv
- In mice, fiber photometry showed the M4 PAM VU0467154 lowered basal dopamine release events but left amphetamine-evoked dopamine largely intact, even though it still blunted antipsychotic-like behavior.
- Mice lacking M4 in the dorsal striatum did not respond to the compound, pointing to postsynaptic striatal M4 signaling as the driver.
💡 PointsBased on the abstractThis weakens the neat story that M4 agents work by pulling dopamine back to normal, and that matters for biomarker choice: a dopamine readout may not tell you whether a clinical M4 candidate is engaging its mechanism. The striatal knockout is the convincing part. It is still one PAM in rodent behavioral models, so I'd hold off on reading it across to patients.
Striatal M4 Receptors Mediate M4 PAM Antipsychotic-like Efficacy Independently of Normalizing Striatal Dopamine Release ↗
2026-10-27 · 🧬Neurotensin receptor 1 (NTSR1) intracellular allosteric modulators (SBI-553 analogs) · bioRxiv
- Chemical variants of the β-arrestin-biased modulator SBI-553 shifted the balance between G-protein and β-arrestin signaling at neurotensin receptor 1.
- Cryo-EM structures of the receptor–effector complexes showed how the pocket reshapes the interface; phosphoproteomics gave each compound a partly distinct signaling fingerprint.
- One analog, N065, improved survival in a lethal mouse endotoxemia model.
💡 PointsBased on the abstractHaving structures that explain why a small substituent changes bias is what turns biased signaling from a descriptive label into something you can design against. The open question for any pharmacologist is which arm actually drives the in vivo phenotype. A survival benefit in endotoxemia from one analog is a hint, not a validated link between bias profile and efficacy, and the non-obvious NTSR1 indication deserves skeptical follow-up.
Fine-tuning an intracellular allosteric pocket programs GPCR signaling bias ↗
2026-10-25 · 🧬Human CYP1A2 / organophosphorus compounds · bioRxiv
- LC-MS/MS metabolism assays and a fluorescence inhibition assay were used to test how human CYP1A2 handles organophosphorus pesticides and nerve agent surrogates.
- Thion forms were turned over more readily than oxon forms, and several compounds inhibited the enzyme in a time- and concentration-dependent manner.
- Docking on a CYP1A2 crystal structure was consistent with the experimental trends.
💡 PointsBased on the abstractThe time-dependent inhibition is what catches my eye: an exposure that quietly inactivates CYP1A2 would shift the clearance of co-administered substrates such as caffeine, theophylline or clozapine. The bioscavenger idea is a stretch from recombinant enzyme work, and I'd want hepatocyte data and realistic exposure levels before reading anything into clinical or occupational risk.
Human CYP1A2 metabolism of organophosphorus pesticides and nerve agent surrogates ↗
2026-10-25 · 🧬CYP3A4 in human macrophages / cocaine–antiretroviral interaction · bioRxiv
- Monocyte-derived macrophages from many donors expressed CYP3A4 with measurable activity, but mRNA, protein and enzyme activity correlated poorly across donors.
- Cocaine raised catalytic activity in every donor, to a level comparable with rifampicin, though its effect on expression varied.
- In rhesus macaques, cocaine coincided with lower tissue antiretroviral levels and higher CYP3A4 and PXR expression.
💡 PointsBased on the abstractExpression-function discordance is a useful warning that mRNA or protein levels alone can mislead in this tissue. If cocaine induces CYP3A4 in the very cells that harbor HIV, tissue-level antiretroviral exposure could fall below what plasma PK suggests, and that is a drug-drug interaction I'd want modeled. The macaque link is correlative so far, and I'd like to see tissue concentrations tied directly to the macrophage effect.
Primary Human Macrophages Exhibit Functional CYP3A4 Activity with Marked Expression-Function Discordance and Cocaine-Induced Catalytic Activation ↗
2026-10-28 · 🏢partnership · Endpoints News · Astellas / Audax Biosciences
- Astellas has taken an exclusive option to license a preclinical immuno-oncology asset, an IL-12 therapy, from Australian biotech Audax Biosciences.
- Per Endpoints, the $285 million figure covers the upfront fee plus a payment that falls due if Astellas exercises the option; the upfront share is not broken out in the available excerpt.
💡 PointsBased on public reportsIL-12 is a potent but historically toxic cytokine, so Astellas is paying for the right to wait for Audax to show it can be dosed safely. An option keeps its commitment small until that data exists, which fits the cautious, optionality-first posture many big players now take with preclinical immuno-oncology.
Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences ↗
2026-10-28 · 🏢trial result · BioPharma Dive · Eli Lilly / Novo Nordisk
- Lilly's Phase 3 TRANSCEND-T2D-2 pitted triple-agonist retatrutide against Ozempic 2 mg in roughly 1,300 adults with type 2 diabetes over 80 weeks, and hit its primary and key secondary endpoints.
- Both retatrutide doses cut A1C more than Ozempic and produced about twice the weight loss; the top dose carried more side effects and discontinuations.
- The trial was open-label and the data are company topline; Lilly plans regulatory filings in early 2027.
💡 PointsBased on public reportsA head-to-head win over the diabetes market's reference product is the evidence payers and prescribers have been waiting for, and it lands on Novo's home turf rather than in obesity. The tolerability gap at the top dose is the caveat to watch: if dropouts hold up in full data, the 9 mg dose may be the commercial workhorse.
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes ↗
2026-10-26 · 🏢trial result · Fierce Biotech · AstraZeneca
- Phase 3 CLARITY-Gastric01 tested the claudin 18.2 ADC sonesitatug vedotin in previously treated CLDN18.2-positive gastric cancer; it met its overall survival primary endpoint in third-line and later patients.
- The progression-free survival endpoint showed a favorable trend in the broader second-line-and-later population but was not statistically significant.
- An AstraZeneca executive told Fierce at ESMO that the dataset is robust enough for regulators; the company also floated broadening the positivity cutoff.
💡 PointsBased on public reportsAn OS win with a PFS miss is a defensible filing in a cancer where survival is the endpoint regulators and payers care about most, but the second-line label is now a negotiation rather than a given. With Takeda's rival ADC posting a clean dual win, AstraZeneca's first-mover claim in claudin 18.2 looks less secure than it did in July.
ESMO: AstraZeneca exec insists phase 3 ADC data 'robust' enough for regulators despite PFS miss ↗
2026-10-26 · 🏢trial result · Fierce Biotech · Takeda / Innovent Biologics
- Phase 3 G-HOPE-001, presented as a late-breaker at ESMO, met its dual primary endpoints of overall and progression-free survival versus physician's-choice chemotherapy in previously treated CLDN18.2-positive gastric cancer.
- The trial enrolled about 460 patients in China and Japan; Fierce reports median overall survival of roughly ten months for the ADC.
- Takeda plans a Japanese filing and says it will pursue global trials in gastric and pancreatic cancer.
💡 PointsBased on public reportsThis validates Takeda's roughly $1.2B Innovent partnership and gives it a real foothold in a claudin 18.2 field that AstraZeneca is also chasing. The open question is exportability: an all China-and-Japan dataset will face questions from FDA, so the global trials Takeda promises are where the asset's value is actually decided.
ESMO: Takeda's $1.2B bet on Innovent 'absolutely' pays off with details of ADC's phase 3 win ↗
2026-10-23 · 🏢regulatory · Fierce Biotech · US Treasury / China-linked biotech deals
- Treasury's proposed rule would add pharmaceutical compounds to the COINS Act outbound-investment regime, covering small molecules, biologics, cell and gene therapies and delivery systems.
- Trade reporting says ordinary in-licensing and fee-for-service R&D collaborations with Chinese companies are largely untouched, while equity stakes, joint ventures and some fund investments are in scope.
- Lawyers flag the NewCo model, where US investors build a company around a licensed Chinese asset, as the most exposed structure; the draft is open for public comment.
💡 PointsBased on public reportsThe carve-out for licensing is what matters for the Big Pharma deal flow of the past year, and the draft leaves the in-licensing playbook intact. The real pressure falls on the capital side: NewCos and US venture money into Chinese biotechs. Expect more structuring around licensing, and lobbying before the comment window closes.
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma's China licensing deals ↗
